This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 12496 results found since Jan 2013.
Higher buprenorphine doses associated with improved retention in treatment for opioid use disorder
NIH-funded study suggests need to reevaluate opioid addiction treatment recommendations in the era of fentanyl
Source: NIDA News - September 18, 2023 Category: Addiction Tags: Addiction Science, Adults, Buprenorphine, Evidence-Based Practices, Opioids, Overdose, Overdose Prevention Centers, Recovery, Relapse and Recovery, Relapse Prevention, Tratamiento, Trauma, Treatment Research, Young Adults, Health and Medical Professionals Source Type: news
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE tablet REMEDYREPACK INC.
Updated Date: Mon, 18 Sep 2023 00:00:00 EDT
Source: DailyMed Drug Label Updates - September 18, 2023 Category: Drugs & Pharmacology Source Type: alerts
Emergency Department Buprenorphine Quality Improvement and Emergency Physician Knowledge, Attitudes, and Self-Efficacy
In this study we evaluated changes in emergency physician knowledge, con fidence, and self-efficacy regarding buprenorphine prescribing and working with patients who use drugs after implementation of an ED buprenorphine quality improvement (QI) initiative.Methods: An anonymous, online survey was administered to emergency physicians staf fing four EDs in New England in 2019 and 2020 before and after an ED QI initiative. Survey questions included novel and previously validated questions to assess confidence, knowledge, self-efficacy, and attitudes about buprenorphine and working with patients who use drugs. Confidence,...
Source: Western Journal of Emergency Medicine - September 15, 2023 Category: Emergency Medicine Authors: Myles, Michelle L. Source Type: research
Patient reported preferences for sleep interventions among women receiving buprenorphine for opioid use disorder
ConclusionsMany women receiving MOUD have concomitant insomnia symptoms, and desire availability of both pharmacologic and behavioral sleep interventions within the OUD treatment setting. Qualitative findings underscore the need for evidence-based sleep interventions that account for the unique socioenvironmental factors that may impact strategy implementation in this population.
Source: Frontiers in Psychiatry - September 14, 2023 Category: Psychiatry Source Type: research
APA Urges Expanded Telemedicine Prescribing Rules in DEA Listening Session
Telemedicine prescribing has expanded access to psychiatric medications —including controlled substances such as buprenorphine, which are crucial to fighting the opioid epidemic. So said psychiatrist Shabana Khan, M.D., yesterday during apublic meeting hosted by the Drug Enforcement Agency (DEA) about its proposed regulations on prescribing controlled substances via telemedicine. Khan, who was invited to speak at the meeting on behalf of APA, is director of child and adolescent telepsychiatry at NYU Langone Health, an assistant professor of child and adolescent psychiatry at NYU Grossman School of Medicine, and chair of ...
Source: Psychiatr News - September 13, 2023 Category: Psychiatry Tags: APA controlled substances DEA DEA rules diversion flexibilities opioid epidemic Shabana Khan telemedicine Source Type: research
The End of the X-waiver: Excitement, Apprehension, and Opportunity
J Am Board Fam Med. 2023 Sep 13:jabfm.2023.230048R1. doi: 10.3122/jabfm.2023.230048R1. Online ahead of print.ABSTRACTWith the passage of the MAT act (Mainstreaming Addiction Treatment) and the MATE Act (Medication Training and Expansion), the Drug Enforcement Agency "X-waiver" program governing the office-based prescription of buprenorphine for opioid use disorder has been immediately eliminated. The move was championed by vocal organizations with a rightful concern about buprenorphine access but was opposed by most physicians. Nonetheless, buprenorphine can now be prescribed like any schedule 3 medication. Studies show th...
Source: American Family Physician - September 13, 2023 Category: Primary Care Authors: Nicholas LeFevre Joshua St Louis Emma Worringer Morgan Younkin Natalie Stahl Mia Sorcinelli Source Type: research
The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial
CONCLUSIONS: Baseline anxiety severity did not significantly impact retention in OAT for adults with POUD, and there was no significant effect modification by OAT type. However, the overall retention rates were low, highlighting the need to develop new strategies to minimize the risk of attrition from treatment.CLINICAL TRIAL REGISTRATION: This study was registered in ClinicalTrials.gov (NCT03033732).PMID:37697811 | DOI:10.1177/07067437231194385
Source: Canadian Journal of Psychiatry - September 12, 2023 Category: Psychiatry Authors: Anees Bahji Gabriel Bastien Paxton Bach JinCheol Choi Bernard Le Foll Ron Lim Didier Jutras-Aswad M Eugenia Socias Source Type: research
